reports
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of ...
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take s...
atai Life Sciences and Beckley Psytech to Combine Creating a Global Le...
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-...
atai Life Sciences to Participate in Upcoming Investor Conferences
atai Life Sciences to Participate in Upcoming Investor Conferences NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company’s management team is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference Format: Fireside ChatDate and Time: Thursday, June 5 at 9:55 A.M. EDTLocation: New YorkWebcast link: H.C. Wainwright 6th Annu...
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
BBDC BARINGS BDC INC.
ENR EDGEWELL PERSONAL CARE COMPANY
INZY INOZYME PHARMA
ALIT ALIGHT
WEST INC. / DELAWARE
STRW WESTROCK COFFEE COMPANY LLC
SRBK STRAWBERRY FIELDS REIT INC.
SDHC SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO EATON VANCE INSD CALIF MUN BD FD
GF MORNINGSTAR PARTNERS
GREE L.P.
HCWB THE NEW GERMANY FUND
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
atai Life Sciences Announces Positive Topline Data from Part 2 of Beck...
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing - Data from the eight-week core, randomized stage of Beckley Psytech’s Phase 2b study of BPL-003 for treatment-resista...
The Pennant Group Appoints Suzanne Snapper as Director
The Pennant Group Appoints Suzanne Snapper as Director EAGLE, Idaho, May 16, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced the appointment of Suzanne D. Snapper to its board of directors following her election by a vote of shareholders in connection with the Company’s annual shareholder meeting. Ms. Snapper is the Chief Financial Officer of the Ensign Group, Inc. (“Ensign”) (NASDAQ: ENSG), a leading publicly-traded provider of skilled nursing services...
- Yun Zhong
- David Nierengarten
- Dennis Pak
- Martin Fan
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provid...
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights - Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company” or “Ino...
atai Life Sciences Reports First Quarter 2025 Financial Results and Re...
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) - the largest controlled trial of mebufotenin and the first and only such trial to investigate mebufotenin in the U.S.Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral R-MDMA) for the treatment of ...
- David Nierengarten
- Dennis Pak
- Martin Fan
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of E...
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo-controlled Phase 2 study will assess the safety, tolerability and efficacy of EMP-01 in adults with social anxiety disorder - Topline data anticipated in the first quarter of 2026 NEW YORK and BERLIN, May 13, 2025 (GLOBE...
Pennant Reports First Quarter 2025 Results
Pennant Reports First Quarter 2025 Results Conference Call and Webcast scheduled for tomorrow, May 7, 2025 at 10:00 am MT EAGLE, Idaho, May 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.22 for the first quarter of 2025. Pennant also reported adjusted diluted earnings per share of $0.27 for the quarter(1). First Quarter Highlights Total revenue for the first q...
Pennant Announces First Quarter 2025 Earnings Release and Call
Pennant Announces First Quarter 2025 Earnings Release and Call EAGLE, Idaho, April 21, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its first quarter 2025 financial results on Tuesday, May 6, 2025. Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management will di...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-Worl...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need for early and improved diagnosis, care and treatments that address the long-term systemic effects of ENPP1 Deficiency - BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative the...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
BPMC BLUEPRINT MEDICINES CORP.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
PINS PINTEREST INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
INZY REVOLUTION MEDICINES
TVTX INOZYME PHARMA
VRDN TRAVERE THERAPEUTICS INC
NUVB VIRIDIAN THERAPEUTICS INC
DAWN NUVATION BIO INC (A)
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
JANX GEMINI THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
NUVL MOONLAKE IMMUNOTHERAPEUTICS
APGE NUVALENT INC
ORKA APOGEE THERAPEUTICS INC
ORUKA THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
BPMC BLUEPRINT MEDICINES CORP.
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
RVMD REVOLUTION MEDICINES
INZY INOZYME PHARMA
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
NUVL NUVALENT INC
APGE APOGEE THERAPEUTICS INC
Pennant Expands Portfolio with Acquisition of Senior Living Community ...
Pennant Expands Portfolio with Acquisition of Senior Living Community in Arizona EAGLE, Idaho, April 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of the real estate and operations of an established senior living community in Arizona. The newly acquired community offers assisted living and memory care services, and increases Pennant’s Arizona operations by 128 units. “This acquisition aligns with our mission to provide lif...
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healt...
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET. A live webcast of the fireside chat can be...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
MG MISTRAS GROUP
LPSN LIVEPERSON INC.
GCO GENESCO INC.
QRHC QUEST RESOURCE HOLDING
CULP CULP INC.
CMCO COLUMBUS MCKINNON CORPORATION
GCBC GREENE COUNTY BANCORP INC.
FLWS 1-800-FLOWERS.COM CL A
GRWG GROWGENERATION
BDTX BLACK DIAMOND THERAPEUTICS
ENX INC.
ECAT EATON VANCE NEW YORK MUNICIPAL BOND FUND
BUKS BLACKROCK ESG CAP ALLOCATION TR
SBGI BUTLER NATIONAL CORP
SRBK SINCLAIR INC
ADVM SR BANCORP INC
SUNS ADVERUM BIOTECHNOLOGIES INC.
SUNRISE REALTY TRUST
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.